The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 02, 2019

Filed:

Jul. 30, 2015
Applicants:

Caprion Biosciences Inc., Montreal, CA;

Val-chum, Limited Partnership, Montreal, CA;

Adaerata, Limited Partnership, Montreal, CA;

Inventors:

Eustache Paramithiotis, Boucherville, CA;

Marc Prentki, Mount-Royal, CA;

Rèmi Rabasa-Lhoret, Montreal, CA;

Pascal Croteau, Laval, CA;

Joel Lanoix, Montreal, CA;

S.R. Murthy Madiraju, Brossard, CA;

Èrik Joly, Blainville, CA;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); G01N 2500/00 (2013.01); G01N 2560/00 (2013.01); G01N 2570/00 (2013.01); G01N 2800/042 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject.


Find Patent Forward Citations

Loading…